DBV Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
DBV Technologies SA Completes EUR 29.9 Million Private Placement
DBV Technologies SA announced the completion of a private placement of new and secondary shares that resulted in gross proceeds for the Company of around EUR 29.9 million. The shares offered under the Private Placement amounted to a total of 2,958,817 shares, split as follows: 1,680,151 new shares issued by means of a capital increase without shareholders' preemptive rights which represents around 12.5% of the outstanding shares prior to the Private Placement; 1,278,666 existing shares stemming from the disposal of shares held by the following shareholders: Lundbeckfond, ALK Abello, Apax Partners, Altamir and Innobio (together the "Selling Shareholders") and representing a total of around 8.5% of the total number of shares outstanding following the issuance of the new shares. Following an accelerated bookbuilding process, the price of the placement has been set at EUR 10.11 per share. This price represents a 5% discount to the volume weighted average price of the last 3 trading days preceding the pricing, i.e. EUR 10.6405. The net proceeds to the Company are estimated to be around EUR 15.5 million. The Private Placement was conducted by Societe Generale Corporate & Investment Banking as Lead Manager and Joint Bookrunner, Kempen & Co as Joint Bookrunner (together the "Joint Bookrunners"), and Trout Capital as United States Placement Agent. The majority of shares were placed with investors in the United States.
Latest Developments for DBV Technologies SA
- DBV Technologies announces proposed global offering for 2.67 mln shares
- DBV Technologies SA announces primary endpoint met in VIPES, Viaskin Peanut's Phase IIb clinical trial in peanut allergy
- DBV Technologies SA files IPO - Form F-1
- DBV Technologies presents preclinical data to support DBV`s EPITTM disease modifying effect
- Share this
- Digg this